Mersana Therapeutics Banner Image

Mersana Therapeutics

  • Ticker MRSN
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Mersana Therapeutics Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
Mersana is rewriting the rules for immunoconjugate therapies by leveraging their Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. Their Fleximer platform allows them to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug’s chances of effectively attacking a particularMore cancer. They engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because they can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana’s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
4.7 / 5.0 (260)

Mersana Therapeutics reports have an aggregate usefulness score of 4.7 based on 260 reviews.

Mersana Therapeutics

Most Recent Annual Report

Mersana Therapeutics
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Mersana Therapeutics Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!